|Systematic (IUPAC) name|
|Biological half-life||5 days (mean)|
|Molar mass||475.354 g/mol[[Script error: No such module "String".]]|
Vandetanib (rINN, proposed trade name Zactima), also known as ZD6474, is an antagonist of the vascular endothelial growth factor receptor (VEGFR) and the epidermal growth factor receptor (EGFR). It is a tyrosine kinase inhibitor.
Drug has a third target: inhibits RET-tyrosine kinase activity, an important growth driver in certain types of thyroid cancer
Vandetanib is being developed by AstraZeneca. It is a medication currently undergoing clinical trials as a potential targeted treatment for non–small-cell lung cancer. There have been some promising results from a phase III trial with docetaxel. There have also been ambivalent results when used with pemetrexed Another trial with docetaxel was recruiting in July 2009. AstraZeneca withdrew regulatory submissions for Zactima in October 2009 after trials showed no benefit when the drug was administered alongside chemotherapy .
- Cancerline.com: Vandetanib Information for Physicians
- AZ-Trials.com: AstraZeneca Clinical Trials Patient Recruiting (US)
Cite error: Invalid
parameter "group" is allowed only.
<references />, or
<references group="..." />
|This pharmacology-related article is a stub. You can help ssf by expanding it.|
- http://www.sciencedaily.com/releases/2009/06/090601092237.htm "Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer" June 2009
- http://www.medpagetoday.com/MeetingCoverage/IASLC/15396 "IASLC: Vandetanib Fails to Improve NSCLC Outcomes with Pemetrexed" Aug 2009
- http://www.guardian.co.uk/business/marketforceslive/2009/oct/28/astrazeneca-glaxosmithkline "AstraZeneca drops after it withdraws submissions for cancer drug"